D by degrading the estrogen receptor (Kansra et al., 2005) and extremely
D by degrading the estrogen receptor (Kansra et al., 2005) and highly efficient antagonist to hormonesensitive breast cancers following failure of earlier tamoxifen or aromatase inhibitor therapies. Even so, following…